We wish to inform you that, the Board of Directors of the Company, at its meeting held today 22nd September, 2025 has inter- alia considered, approved and taken on record 1. Change of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Remedium Lifecare Limited (proposing to rename to Supha Pharmachem, Supha Pharmachem, or Solva Pharmachem) approved three key items on 22nd September 2025. First, the company will change its name to better reflect its expanded business operations and strategic growth. Second, the authorised share capital will be raised from ₹110 crore to ₹210 crore, nearly doubling the existing limit. Third, the Board approved a proposal to raise up to ₹100 crore through instruments such as a Qualified Institutions Placement (QIP), Rights Issue, or a combination of both. The funds are intended to strengthen the balance sheet, support business expansion, and meet general corporate purposes. All three items remain subject to shareholder and regulatory approvals.
The name change signals a strategic repositioning toward the pharma/chem space, while the capital increase and ₹100 crore fund-raising plan indicate the company is preparing for significant business expansion. Shareholders may see potential dilution depending on the final mode and pricing of the issue, but no immediate price impact is expected until further details are disclosed.